Intraperitoneal Chemotherapy from Armstrong to HIPEC: Challenges and Promise

Ramez N. Eskander, James Cripe, Robert E. Bristow

Research output: Contribution to journalArticle

Abstract

The treatment of advanced stage ovarian, primary peritoneal and fallopian tube cancer represents a therapeutic challenge as evidenced by the 70 %-80 % recurrence rate. Our understanding of the synergy between surgical cytoreduction and effective systemic chemotherapy continues to evolve, with research supporting maximal cytoreductive effort followed by intraperitoneal chemotherapy. Specifically, analysis of phase III clinical trials has shown a median survival of 110 months in those treated with intraperitoneal chemotherapy, when surgery results in no visible residual disease. Additionally, incorporation of hyperthermic intraperitoneal chemotherapy at the time of surgical resection has gained attention as an alternate therapeutic option, in an attempt to obviate toxicities encountered with repetitive cycles of intraperitoneal chemotherapy. Currently, surgical cytoreduction in the hands of an experienced gynecologic oncologist, followed by intraperitoneal chemotherapy is thought to portend the greatest survival benefit in patients with advanced stage ovarian cancer spectrum cancers. Additional investigation regarding the oncologic outcomes and morbidity of hyperthermic intraperitoneal chemotherapy is warranted.

Original languageEnglish (US)
Pages (from-to)27-40
Number of pages14
JournalCurrent Treatment Options in Oncology
Volume15
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Drug Therapy
Fallopian Tube Neoplasms
Phase III Clinical Trials
Survival
Ovarian Neoplasms
Therapeutics
Morbidity
Recurrence
Research
Neoplasms

Keywords

  • Cytoreductive surgery
  • HIPEC
  • Intraperitoneal chemotherapy
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Intraperitoneal Chemotherapy from Armstrong to HIPEC : Challenges and Promise. / Eskander, Ramez N.; Cripe, James; Bristow, Robert E.

In: Current Treatment Options in Oncology, Vol. 15, No. 1, 2014, p. 27-40.

Research output: Contribution to journalArticle

Eskander, Ramez N. ; Cripe, James ; Bristow, Robert E. / Intraperitoneal Chemotherapy from Armstrong to HIPEC : Challenges and Promise. In: Current Treatment Options in Oncology. 2014 ; Vol. 15, No. 1. pp. 27-40.
@article{c69fdb25f3a64262b964c813c54d76ca,
title = "Intraperitoneal Chemotherapy from Armstrong to HIPEC: Challenges and Promise",
abstract = "The treatment of advanced stage ovarian, primary peritoneal and fallopian tube cancer represents a therapeutic challenge as evidenced by the 70 {\%}-80 {\%} recurrence rate. Our understanding of the synergy between surgical cytoreduction and effective systemic chemotherapy continues to evolve, with research supporting maximal cytoreductive effort followed by intraperitoneal chemotherapy. Specifically, analysis of phase III clinical trials has shown a median survival of 110 months in those treated with intraperitoneal chemotherapy, when surgery results in no visible residual disease. Additionally, incorporation of hyperthermic intraperitoneal chemotherapy at the time of surgical resection has gained attention as an alternate therapeutic option, in an attempt to obviate toxicities encountered with repetitive cycles of intraperitoneal chemotherapy. Currently, surgical cytoreduction in the hands of an experienced gynecologic oncologist, followed by intraperitoneal chemotherapy is thought to portend the greatest survival benefit in patients with advanced stage ovarian cancer spectrum cancers. Additional investigation regarding the oncologic outcomes and morbidity of hyperthermic intraperitoneal chemotherapy is warranted.",
keywords = "Cytoreductive surgery, HIPEC, Intraperitoneal chemotherapy, Ovarian cancer",
author = "Eskander, {Ramez N.} and James Cripe and Bristow, {Robert E.}",
year = "2014",
doi = "10.1007/s11864-013-0264-2",
language = "English (US)",
volume = "15",
pages = "27--40",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Intraperitoneal Chemotherapy from Armstrong to HIPEC

T2 - Challenges and Promise

AU - Eskander, Ramez N.

AU - Cripe, James

AU - Bristow, Robert E.

PY - 2014

Y1 - 2014

N2 - The treatment of advanced stage ovarian, primary peritoneal and fallopian tube cancer represents a therapeutic challenge as evidenced by the 70 %-80 % recurrence rate. Our understanding of the synergy between surgical cytoreduction and effective systemic chemotherapy continues to evolve, with research supporting maximal cytoreductive effort followed by intraperitoneal chemotherapy. Specifically, analysis of phase III clinical trials has shown a median survival of 110 months in those treated with intraperitoneal chemotherapy, when surgery results in no visible residual disease. Additionally, incorporation of hyperthermic intraperitoneal chemotherapy at the time of surgical resection has gained attention as an alternate therapeutic option, in an attempt to obviate toxicities encountered with repetitive cycles of intraperitoneal chemotherapy. Currently, surgical cytoreduction in the hands of an experienced gynecologic oncologist, followed by intraperitoneal chemotherapy is thought to portend the greatest survival benefit in patients with advanced stage ovarian cancer spectrum cancers. Additional investigation regarding the oncologic outcomes and morbidity of hyperthermic intraperitoneal chemotherapy is warranted.

AB - The treatment of advanced stage ovarian, primary peritoneal and fallopian tube cancer represents a therapeutic challenge as evidenced by the 70 %-80 % recurrence rate. Our understanding of the synergy between surgical cytoreduction and effective systemic chemotherapy continues to evolve, with research supporting maximal cytoreductive effort followed by intraperitoneal chemotherapy. Specifically, analysis of phase III clinical trials has shown a median survival of 110 months in those treated with intraperitoneal chemotherapy, when surgery results in no visible residual disease. Additionally, incorporation of hyperthermic intraperitoneal chemotherapy at the time of surgical resection has gained attention as an alternate therapeutic option, in an attempt to obviate toxicities encountered with repetitive cycles of intraperitoneal chemotherapy. Currently, surgical cytoreduction in the hands of an experienced gynecologic oncologist, followed by intraperitoneal chemotherapy is thought to portend the greatest survival benefit in patients with advanced stage ovarian cancer spectrum cancers. Additional investigation regarding the oncologic outcomes and morbidity of hyperthermic intraperitoneal chemotherapy is warranted.

KW - Cytoreductive surgery

KW - HIPEC

KW - Intraperitoneal chemotherapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84894683152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894683152&partnerID=8YFLogxK

U2 - 10.1007/s11864-013-0264-2

DO - 10.1007/s11864-013-0264-2

M3 - Article

C2 - 24338278

AN - SCOPUS:84894683152

VL - 15

SP - 27

EP - 40

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1

ER -